Parvus Therapeutics said today that it signed an exclusive worldwide license and collaboration deal with Novartis (NYSE:NVS) for its type 1 diabetes nanodrug, Navacim. The therapeutic candidate is made up of iron oxide nanoparticles coated with a peptide derived from a pancreatic autoantigen, according to Parvus.
Navacims are the 1st biopharmaceuticals to restore immune tolerance through the formation of regulatory T-cells in prelinical models without suppressing the immune system, the company reported.
Get the full story at our sister site, Drug Delivery Business News.